Omega-3 Polyunsaturated Fatty Acids and the Treatment of Rheumatoid Arthritis

A Meta-analysis

Young Ho Lee, Sang Cheol Bae, Gwan Gyu Song

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background and Aims: We undertook this study to assess the effects of omega-3 polyunsaturated fatty acids (PUFAs) (administered at ≥2.7 g/day) for a minimum duration of 3 months on clinical outcomes in patients with rheumatoid arthritis (RA). Methods: The authors surveyed randomized controlled trials (RCTs) that examined the effects of omega-3 PUFAs on clinical outcomes in RA patients using Medline and the Cochrane Controlled Trials Register and by performing manual searches. Meta-analysis of RCTs was performed using fixed and random effects models. Outcomes are presented as standardized mean differences (SMD). Results: Ten RCTs involving 183 RA patients and 187 placebo-treated RA controls were included in this meta-analysis. The analysis showed that omega-3 PUFAs clearly reduced nonsteroidal anti-inflammatory drug (NSAID) consumption (SMD -0.518, 95% CI -0.915 to -0.121, p = 0.011) without between-study heterogeneity (I2 = 0%). Tender joint count (SMD -0.214, 95% CI-0.489-0.062, p = 0.128), swollen joint count (SMD -0.170, 95% CI-0.454-0.114, p = 0.241), morning stiffness (SMD -0.224, 95% CI-0.955-0.212, p = 0.221), and physical function (SMD 0.264, 95% CI-0.232-0.724, p = 0.314) showed a trend to improve more in patients treated with omega-3 PUFAs than in placebo-treated controls, but they did not reach statistical significance. Conclusions: This meta-analysis suggests that the use of omega-3 PUFAs at dosages >2.7 g/day for >3 months reduces NSAID consumption by RA patients. Further studies are needed to explore the clinical and NSAID-sparing effects of omega-3 PUFAs in RA.

Original languageEnglish
Pages (from-to)356-362
Number of pages7
JournalArchives of Medical Research
Volume43
Issue number5
DOIs
Publication statusPublished - 2012 Jul 1

Fingerprint

Omega-3 Fatty Acids
Unsaturated Fatty Acids
Meta-Analysis
Rheumatoid Arthritis
Anti-Inflammatory Agents
Randomized Controlled Trials
Therapeutics
Joints
Placebos
Pharmaceutical Preparations

Keywords

  • Omega-3 polyunsaturated fatty acids
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Omega-3 Polyunsaturated Fatty Acids and the Treatment of Rheumatoid Arthritis : A Meta-analysis. / Lee, Young Ho; Bae, Sang Cheol; Song, Gwan Gyu.

In: Archives of Medical Research, Vol. 43, No. 5, 01.07.2012, p. 356-362.

Research output: Contribution to journalArticle

@article{a9f1190bc69b4fd6b23f29dd0777a4c1,
title = "Omega-3 Polyunsaturated Fatty Acids and the Treatment of Rheumatoid Arthritis: A Meta-analysis",
abstract = "Background and Aims: We undertook this study to assess the effects of omega-3 polyunsaturated fatty acids (PUFAs) (administered at ≥2.7 g/day) for a minimum duration of 3 months on clinical outcomes in patients with rheumatoid arthritis (RA). Methods: The authors surveyed randomized controlled trials (RCTs) that examined the effects of omega-3 PUFAs on clinical outcomes in RA patients using Medline and the Cochrane Controlled Trials Register and by performing manual searches. Meta-analysis of RCTs was performed using fixed and random effects models. Outcomes are presented as standardized mean differences (SMD). Results: Ten RCTs involving 183 RA patients and 187 placebo-treated RA controls were included in this meta-analysis. The analysis showed that omega-3 PUFAs clearly reduced nonsteroidal anti-inflammatory drug (NSAID) consumption (SMD -0.518, 95{\%} CI -0.915 to -0.121, p = 0.011) without between-study heterogeneity (I2 = 0{\%}). Tender joint count (SMD -0.214, 95{\%} CI-0.489-0.062, p = 0.128), swollen joint count (SMD -0.170, 95{\%} CI-0.454-0.114, p = 0.241), morning stiffness (SMD -0.224, 95{\%} CI-0.955-0.212, p = 0.221), and physical function (SMD 0.264, 95{\%} CI-0.232-0.724, p = 0.314) showed a trend to improve more in patients treated with omega-3 PUFAs than in placebo-treated controls, but they did not reach statistical significance. Conclusions: This meta-analysis suggests that the use of omega-3 PUFAs at dosages >2.7 g/day for >3 months reduces NSAID consumption by RA patients. Further studies are needed to explore the clinical and NSAID-sparing effects of omega-3 PUFAs in RA.",
keywords = "Omega-3 polyunsaturated fatty acids, Rheumatoid arthritis",
author = "Lee, {Young Ho} and Bae, {Sang Cheol} and Song, {Gwan Gyu}",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.arcmed.2012.06.011",
language = "English",
volume = "43",
pages = "356--362",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Omega-3 Polyunsaturated Fatty Acids and the Treatment of Rheumatoid Arthritis

T2 - A Meta-analysis

AU - Lee, Young Ho

AU - Bae, Sang Cheol

AU - Song, Gwan Gyu

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Background and Aims: We undertook this study to assess the effects of omega-3 polyunsaturated fatty acids (PUFAs) (administered at ≥2.7 g/day) for a minimum duration of 3 months on clinical outcomes in patients with rheumatoid arthritis (RA). Methods: The authors surveyed randomized controlled trials (RCTs) that examined the effects of omega-3 PUFAs on clinical outcomes in RA patients using Medline and the Cochrane Controlled Trials Register and by performing manual searches. Meta-analysis of RCTs was performed using fixed and random effects models. Outcomes are presented as standardized mean differences (SMD). Results: Ten RCTs involving 183 RA patients and 187 placebo-treated RA controls were included in this meta-analysis. The analysis showed that omega-3 PUFAs clearly reduced nonsteroidal anti-inflammatory drug (NSAID) consumption (SMD -0.518, 95% CI -0.915 to -0.121, p = 0.011) without between-study heterogeneity (I2 = 0%). Tender joint count (SMD -0.214, 95% CI-0.489-0.062, p = 0.128), swollen joint count (SMD -0.170, 95% CI-0.454-0.114, p = 0.241), morning stiffness (SMD -0.224, 95% CI-0.955-0.212, p = 0.221), and physical function (SMD 0.264, 95% CI-0.232-0.724, p = 0.314) showed a trend to improve more in patients treated with omega-3 PUFAs than in placebo-treated controls, but they did not reach statistical significance. Conclusions: This meta-analysis suggests that the use of omega-3 PUFAs at dosages >2.7 g/day for >3 months reduces NSAID consumption by RA patients. Further studies are needed to explore the clinical and NSAID-sparing effects of omega-3 PUFAs in RA.

AB - Background and Aims: We undertook this study to assess the effects of omega-3 polyunsaturated fatty acids (PUFAs) (administered at ≥2.7 g/day) for a minimum duration of 3 months on clinical outcomes in patients with rheumatoid arthritis (RA). Methods: The authors surveyed randomized controlled trials (RCTs) that examined the effects of omega-3 PUFAs on clinical outcomes in RA patients using Medline and the Cochrane Controlled Trials Register and by performing manual searches. Meta-analysis of RCTs was performed using fixed and random effects models. Outcomes are presented as standardized mean differences (SMD). Results: Ten RCTs involving 183 RA patients and 187 placebo-treated RA controls were included in this meta-analysis. The analysis showed that omega-3 PUFAs clearly reduced nonsteroidal anti-inflammatory drug (NSAID) consumption (SMD -0.518, 95% CI -0.915 to -0.121, p = 0.011) without between-study heterogeneity (I2 = 0%). Tender joint count (SMD -0.214, 95% CI-0.489-0.062, p = 0.128), swollen joint count (SMD -0.170, 95% CI-0.454-0.114, p = 0.241), morning stiffness (SMD -0.224, 95% CI-0.955-0.212, p = 0.221), and physical function (SMD 0.264, 95% CI-0.232-0.724, p = 0.314) showed a trend to improve more in patients treated with omega-3 PUFAs than in placebo-treated controls, but they did not reach statistical significance. Conclusions: This meta-analysis suggests that the use of omega-3 PUFAs at dosages >2.7 g/day for >3 months reduces NSAID consumption by RA patients. Further studies are needed to explore the clinical and NSAID-sparing effects of omega-3 PUFAs in RA.

KW - Omega-3 polyunsaturated fatty acids

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84866156844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866156844&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2012.06.011

DO - 10.1016/j.arcmed.2012.06.011

M3 - Article

VL - 43

SP - 356

EP - 362

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 5

ER -